PubMed · 6123597
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J Meyerhoff. Systemic necrotizing vasculitis--disease activity, immune complexes.. https://pubmed.ncbi.nlm.nih.gov/6123597/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Intravenously applied human IgG has beneficial effects in treating inflammatory diseases, presumably because it has a complement attenuating role. This role of IgG was studied in vitro by following C3 activation and inactivation in sera that were supplemented with exogenous human IgG and incubated with immune aggregates. IgG added at 2 to 10 mg/mL stimulated the physiologic inactivation of C3b-containing complexes twofold to threefold in 20% sera. This, in turn, lowered the overall C3 activation by 28%, as new C3 convertases primarily assembled on C3b-containing complexes. Exogenous IgG (5 mg/mL) also stimulated inactivation of purified C3b2-IgG complexes, whereby their half-life dropped from 3-4 to 1.5 minutes in 20% serum. IgG appeared to act like a modulator of factor H and I because it did not stimulate inactivation of C3b-containing complexes in factor I-deficient serum. Thus, the known partial protection of C3bn-IgG complexes from inactivation by factor H and I was downregulated by high concentrations of IgG. The ability of high doses of IgG to stimulate complement inactivation is a novel regulatory role of IgG. This may be one of the molecular principles for its therapeutic efficacy in treating complement-mediated inflammations.
HIV-1-infected quiescent CD4+ cells harbor the virus in an inactive state until subsequent activation. The possibility that HIV-1 itself and the virus envelope glycoprotein 120 (gp120) might be important agents of this activation was investigated. The present data indicate that binding of heat-inactivated HIV-1 (iHIV-1) to infected resting PBMCs was sufficient to activate NF-kappa B and AP-1, to induce transition from the G0/G1 stage of the cell cycle to the S/G2/M stage, to induce cell surface expression of CD25, to stimulate provirus integration, and to commit cells to produce virus. The cumulative amount of HIV-1 produced by iHIV-1-stimulated cells strictly depended on the concentration of p24gag in the virion preparations used for stimulation. Moreover, virus production was not evidenced in infected resting cells exposed to iHIV-1 previously incubated with soluble CD4 (sCD4), indicating that activation requires a contact between HIV-1 envelope glycoproteins and cell surface CD4. Although soluble gp120 did not stimulate virus production, we found that transition to the S/G2/M stage of the cell cycle, cell surface expression of activation Ags, and virus production were stimulated by cross-linking of CD4 by gp120-anti-gp120 immune complexes. Finally, incubation of gp120-anti-gp120 immune complexes with sCD4 inhibited these effects. These findings suggest that virions and gp120 anti-gp120 immune complexes found in infected patients at all times of infection can stimulate virus production in CD4+ cells harboring HIV-1 in an inducible state.
The authors characterize the possible role of circulating autoantibodies specific for Fc gamma receptors in autoimmune diseases. Dysfunction of Fc gamma receptors, resulting in prolonged clearance of immune complexes, has been observed in both systemic and organ specific autoimmune disorders. Although the mechanism of the defective Fc gamma receptor function is not clearly understood, some findings suggest that Fc gamma receptor specific autoantibodies may have significant part in these processes. The authors found high titers of anti-Fc gamma receptor autoantibodies in the sera of several mouse strains prone to autoimmune diseases, and then extended these observations to human autoimmune diseases. They analized the specificity and functional effects of these antibodies. The authors hypothesize, that Fc gamma receptor specific autoantibodies may play a role in the pathology of autoimmune diseases by stimulating Fc gamma-receptor-bearing cells to release oxygen intermediates, different lysosomal hydrolases and cytokines or by blocking the phagocytosis of immune complexes.